Drugs / Satraplatin
Satraplatin
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01259479 | Dec 2010 → Aug 2013 | metastatic malignant neoplasm in the brain | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01220284 | Feb 2008 → Nov 2010 | cancer | Southern Europe New Drug Organization | Unknown | No outcome recorded |
| Phase 1 | NCT00473720 | May 2007 → Jun 2010 | high grade malignant neoplasm | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00480623 | May 2007 → Mar 2008 | prostate cancer | Agennix | Terminated | No outcome recorded |
| Phase 1 | NCT00125411 | Mar 2007 → Feb 2009 | neoplasm | Agennix | Terminated | No outcome recorded |
| Phase 1 | NCT00329329 | May 2006 → Jan 2009 | cancer | Agennix | Terminated | No outcome recorded |
| Phase 1 | NCT00313456 | Mar 2006 → Mar 2009 | prostate cancer | Agennix | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00093132 | Aug 2004 → Jan 2009 | non-small cell lung carcinoma | Agennix | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01289067 | Dec 2010 → May 2013 | prostate cancer | William K. Oh | Completed | No outcome recorded |
| Phase 2 | NCT00634647 | Feb 2008 → Feb 2011 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00370383 | Jul 2006 → Feb 2009 | lung cancer | Agennix | Completed | No outcome recorded |
| Phase 2 | NCT00268970 | Dec 2005 → Apr 2007 | non-small cell lung carcinoma | Agennix | Completed | No outcome recorded |
| Phase 2 | NCT00265655 | Nov 2005 → Jan 2008 | breast cancer | Agennix | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03258320 | Jan 2015 → Dec 2026 expected | prostate cancer | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00450970 | Feb 2007 → Mar 2009 | prostate cancer | Agennix | Terminated | No outcome recorded |
| Phase 3 | NCT00069745 | Sep 2003 → Jan 2006 | hormone-resistant prostate carcinoma | Agennix | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00499694 | Oct 2007 → Nov 2012 | prostate cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | satraplatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00499694 ↗ |
| Known as | - Satraplatin (codenamed JM216) | “- Satraplatin (codenamed JM216)” NCT01220284 ↗ |
| Known as | bis-aceto-ammine dischlorocyclohexylamine platinum | “Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue” NCT00370383 ↗ |
| Known as | BMS-182751 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367 ↗ |
| Known as | BMY-45594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367 ↗ |
| Known as | JM-216 | “Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of...” NCT00450970 ↗2“Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue” NCT00370383 ↗ “investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel” NCT00125411 ↗ |
| Known as | NSC-744226 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367 ↗ |
| Known as | OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV) | “Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of...” NCT00450970 ↗ |
| Known as | Satraplatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367 ↗ |
| Known as | Satraplatino | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833367 ↗ |
| Modality | Other / unclassified | “member of the platinum-based class of chemotherapy drugs” NCT00125411 ↗ |
| Route | Oral | “satraplatin can be given orally” NCT00069745 ↗ |